Reader TTS

A recently published study suggests that sirolimus is an attractive treatment option for the prevention of secondary skin cancer in kidney transplant recipients. However, before we think

about switching all patients with a previous skin cancer (or with any other malignancy) to sirolimus, we should have a closer look at the data. Access through your institution Buy or

subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online

access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Ulrich, C., Kanitakis,

J., Stockfleth, E. & Euvrard, S. Skin cancer in organ transplant recipients—where do we stand today? _Am. J. Transplant._ 8, 2192–2198 (2008). Article  CAS  Google Scholar  * Halleck, F.

_ et al_. An evaluation of sirolimus in renal transplantation. _Expert Opin. Drug Metab. Toxicol._ http://dx.doi.org/10.1517/17425255.2012.719874. * Campbell, S. B., Walker, R., Tai, S. S.,

Jiang, Q. & Russ, G. R. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. _Am. J. Transplant._ 12, 1146–1156 (2012).

Article  CAS  Google Scholar  * de Fijter, J. W. _ et al_. Reduced cutaneous squamous cell carcinoma after conversion to sirolimus: a 2-year prospective open-label multicenter trial

[abstract #450]. Presented at the American Transplant Congress 2012. * Mathew, T., Kreis, H. & Friend, P. Two-year incidence of malignancy in sirolimus-treated renal transplant

recipients: results from five multicenter studies. _Clin. Transplant._ 18, 446–449 (2004). Article  Google Scholar  * Salgo, R. _ et al_. Switch to a sirolimus-based immunosuppression in

long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. _Am. J.

Transplant._ 10, 1385–1393 (2010). Article  CAS  Google Scholar  * Euvrard, S. _ et al_. Sirolimus and secondary skin-cancer prevention in kidney transplantation. _N. Engl. J. Med._ 367,

329–339 (2012). Article  CAS  Google Scholar  * Campistol, J. M. _ et al_. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

_J. Am. Soc. Nephrol._ 17, 581–589 (2006). Article  CAS  Google Scholar  * Alberú, J. _ et al_. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin

inhibitor-free immunotherapy: 24-month results from the CONVERT trial. _Transplantation_ 92, 303–310 (2011). Article  Google Scholar  * Cravedi, P., Ruggenenti, P. & Remuzzi, G.

Sirolimus for calcineurin inhibitors in organ transplantation: contra. _Kidney Int._ 78, 1068–1074 (2010). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Department of Nephrology, Charité Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany Fabian Halleck & Klemens Budde Authors * Fabian Halleck View author

publications You can also search for this author inPubMed Google Scholar * Klemens Budde View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING

AUTHOR Correspondence to Fabian Halleck. ETHICS DECLARATIONS COMPETING INTERESTS Klemens Budde has received research grants and/or honoraria from AiCuris, Astellas, Bristol-Myers Squibb,

Hexal, Novartis Pharma, Pfizer, Roche, Siemens, TCL Pharma und Veloxis Pharma. Fabian Halleck declares no competing interests. SUPPLEMENTARY INFORMATION SUPPLEMENTARY TABLE 1 Prospective

RCTs investigating the effect of conversion to sirolimus in patients with skin tumours (DOC 45 kb) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE

Halleck, F., Budde, K. Sirolimus for secondary SCC prevention in renal transplantation. _Nat Rev Nephrol_ 8, 687–689 (2012). https://doi.org/10.1038/nrneph.2012.216 Download citation *

Published: 02 October 2012 * Issue Date: December 2012 * DOI: https://doi.org/10.1038/nrneph.2012.216 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative